EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Regulatory Alignment on Surrogate Endpoints for Slowly Progressive Ultra-Rare Neurological Diseases: Bridging the Gap Between Biomarker Science and Global Regulatory Acceptance

Shihshuan Fang, Shenghan Chen

Therapeutic Innovation & Regulatory Science · 2026-11 · 60 (6) · 1612-1618

DOI: 10.1007/s43441-026-01026-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 29.07.2026. Verfasst von Shihshuan Fang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Landseed International Hospital, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Rare Diseases, Drug Approval, Biomarkers, Nervous System Diseases. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For slowly progressive ultra-rare diseases, hard clinical endpoints such as mortality or sustained functional decline are often impractical within feasible trial timeframes. Surrogate biomarkers, including fluid and imaging analytes, offer a pathway to accelerate drug development. Achieving cross-jurisdictional regulatory acceptance for these surrogates remains a profound scientific and policy challenge.

Methods

We conducted a narrative synthesis incorporating regulatory guidance documents from the FDA, EMA, and NMPA, alongside PubMed-indexed literature on surrogate endpoint validation, orphan drug approval, and biomarker qualification programs published up to early 2026.

Results

The FDA’s Accelerated Approval pathway and the EMA’s Conditional Marketing Authorization represent the primary regulatory vehicles for surrogate-based approvals. A four-tier validation model is proposed, incorporating mechanistic plausibility, epidemiological association, quantitative surrogacy statistics, and confirmatory post-approval requirements. Case studies from neurology (spinal muscular atrophy) and metabolic disorders (lysosomal storage diseases) illustrate the context-of-use dependency of these surrogates. Cross-jurisdictional divergence in evidentiary standards and the absence of a dedicated ICH guideline for rare disease surrogate endpoints constitute major structural gaps.

Conclusions

A globally harmonized evidentiary framework for surrogate endpoint qualification in ultra-rare diseases is urgently needed. Validating this framework in the ultra-rare space could serve as a stepping stone for broader rare disease drug development. Bayesian adaptive designs, international consortium registries, and real-world evidence frameworks are key enabling strategies for addressing the inherent sample-size constraints of this research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesDrug ApprovalBiomarkersNervous System DiseasesHumansUnited StatesUnited States Food and Drug AdministrationOrphan Drug ProductionEndpoint Determination

Stichwörter der Autor:innen

Accelerated approvalBiomarkerHealth policyRegulatory scienceSurrogate endpointUltra-rare disease

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Geriatrics, Landseed International Hospital, Taoyuan, Taiwan.
  • Department of Neurology, Landseed International Hospital, 77 Guangtai Road, Pingzhen District, Taoyuan, 324, Taiwan. castal2008@gmail.com.

Zitieren

APA

Fang, S., & Chen, S. (2026). Regulatory Alignment on Surrogate Endpoints for Slowly Progressive Ultra-Rare Neurological Diseases: Bridging the Gap Between Biomarker Science and Global Regulatory Acceptance. Therapeutic Innovation & Regulatory Science, 60(6), 1612-1618. https://doi.org/10.1007/s43441-026-01026-7

Vancouver

Fang S, Chen S. Regulatory Alignment on Surrogate Endpoints for Slowly Progressive Ultra-Rare Neurological Diseases: Bridging the Gap Between Biomarker Science and Global Regulatory Acceptance. Therapeutic Innovation & Regulatory Science. 2026;60(6):1612-1618. doi:10.1007/s43441-026-01026-7

BibTeX
@article{Fang2026,
  author = {Fang, Shihshuan and Chen, Shenghan},
  title = {Regulatory Alignment on Surrogate Endpoints for Slowly Progressive Ultra-Rare Neurological Diseases: Bridging the Gap Between Biomarker Science and Global Regulatory Acceptance},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {6},
  pages = {1612--1618},
  doi = {10.1007/s43441-026-01026-7}
}
Kostenlos starten →